These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10328304)

  • 1. New synthetic heparin mimetics able to inhibit thrombin and factor Xa.
    Petitou M; Duchaussoy P; Driguez PA; Hérault JP; Lormeau JC; Herbert JM
    Bioorg Med Chem Lett; 1999 Apr; 9(8):1155-60. PubMed ID: 10328304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics.
    Petitou M; Driguez PA; Duchaussoy P; Hérault JP; Lormeau JC; Herbert JM
    Bioorg Med Chem Lett; 1999 Apr; 9(8):1161-6. PubMed ID: 10328305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment through chemical synthesis of the size of the heparin sequence involved in thrombin inhibition.
    Duchaussoy P; Jaurand G; Driguez PA; Lederman I; Ceccato ML; Gourvenec F; Strassel JM; Sizun P; Petitou M; Herbert JM
    Carbohydr Res; 1999 Apr; 317(1-4):85-99. PubMed ID: 10466208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental proof for the structure of a thrombin-inhibiting heparin molecule.
    Petitou M; Imberty A; Duchaussoy P; Driguez PA; Ceccato ML; Gourvenec F; Sizun P; Hérault JP; Pérez S; Herbert JM
    Chemistry; 2001; 7(4):858-73. PubMed ID: 11288878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers.
    Dreef-Tromp CM; Basten JE; Broekhoven MA; van Dinther TG; Petitou M; van Boeckel CA
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2081-6. PubMed ID: 9873490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New antithrombotic oligosaccharides].
    Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
    Ann Pharm Fr; 1999 May; 57(3):232-9. PubMed ID: 10427858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SR123781A, a synthetic heparin mimetic.
    Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
    Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity.
    Grootenhuis PD; Westerduin P; Meuleman D; Petitou M; van Boeckel CA
    Nat Struct Biol; 1995 Sep; 2(9):736-9. PubMed ID: 7552742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma.
    Ofosu FA; Choay J; Anvari N; Smith LM; Blajchman MA
    Eur J Biochem; 1990 Oct; 193(2):485-93. PubMed ID: 2226466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma.
    Schoen P; Lindhout T; Hemker HC
    Br J Haematol; 1992 Jun; 81(2):255-62. PubMed ID: 1322691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of thrombin-inhibiting heparin mimetics without side effects.
    Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
    Nature; 1999 Apr; 398(6726):417-22. PubMed ID: 10201371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [From heparin to synthetic antithrombotic oligosaccharides].
    Petitou M
    Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of new synthetic heparin mimetics.
    Hérault JP; Bernat A; Roye F; Michaux C; Schaeffer P; Bono F; Petitou M; Herbert JM
    Thromb Haemost; 2002 Jun; 87(6):985-9. PubMed ID: 12083506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans.
    Carson L; Doctor VM
    Thromb Res; 1990 May; 58(4):367-81. PubMed ID: 1972302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a hexasaccharide sequence able to inhibit thrombin and suitable for 'polymerisation'.
    Duchaussoy P; Jaurand G; Driguez PA; Lederman I; Gourvenec F; Strassel JM; Sizun P; Petitou M; Herbert JM
    Carbohydr Res; 1999 Apr; 317(1-4):63-84. PubMed ID: 10466207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues.
    Jeske W; Fareed J
    Semin Thromb Hemost; 1993; 19 Suppl 1():241-7. PubMed ID: 8362268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysine-heparin interactions in antithrombin. Properties of K125M and K290M,K294M,K297M variants.
    Fan B; Turko IV; Gettins PG
    Biochemistry; 1994 Nov; 33(47):14156-61. PubMed ID: 7947827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans.
    Noti C; Seeberger PH
    Chem Biol; 2005 Jul; 12(7):731-56. PubMed ID: 16039522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa.
    Scully MF; Ellis V; Shah N; Kakkar V
    Biochem J; 1989 Sep; 262(2):651-8. PubMed ID: 2529852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.